RNA interference technology (RNAi) is the use of double-stranded RNA-induced sequence-specific gene silencing, by regulating and shutting down the expression of genes so that the cell exhibits the phenotype of a specific gene deletion. The expression of specific genes can be specifically deleted or turned off using RNAi technology, so the technology has been widely used in the field of exploring gene function and gene therapy for a variety of diseases. CD Formulation utilizes cutting-edge RNA interference technology to support all phases of gene therapy formulation projects from development to production, and to assist in the research of your project.

Challenges in RNA Interference Technology

Challenges faced by RNA interference technology in practical applications mainly include low transfection efficiency, insufficient specificity, stability and persistence issues, and potential nonspecific effects. The most prominent problem is the efficient transfection of siRNA into cells, especially for primary cells that are difficult to transfect. It is important to note that even a single base mismatch between the siRNA and the target sequence may attenuate the effect of RNAi and may affect the function of other genes that are similar but not identical, increasing the risk of off-targeting. In addition, the issue of siRNA stability and persistence is also a limiting factor, and although chemical modification can improve the stability of siRNAs, it also implies an increase in cost. When RNA interference technology is applied, high concentration and prolonged shRNA expression may lead to cellular damage, which requires us to strictly control the dose of shRNA. We overcome the problems in the practical application of this technology by continuously optimizing and innovating RNA interference technology to maximize the potential of RNAi technology in the field of gene therapy.

Our Novel RNA Interference Technology

Chemically synthesized RNAi services

We can customize our chemical synthesis RNAi services according to customer requirements. From the careful design of double-stranded RNAi constructs to the synthesis of siRNA, we can ensure the highest quality and accuracy. The process extends to transfection into mammalian cells, and ultimately to detection and analysis of inhibition, each stage of which is critical to achieving effective gene silencing.

In the development of gene therapy formulations, customized RNA molecules provide an effective method of silencing specific genes, offering a reliable solution for the development of macro gene therapy formulations.

Vector-mediated RNAi service

Vector-mediated RNAi service involves the embedding of small RNAs, such as short hairpin RNAs (shRNAs), into viral or non-viral vectors to achieve stable, long-term gene silencing. This technology is of even greater importance in gene therapy research where durable suppression of gene expression is required.

Our expertise in the development of a wide range of vectors allows us to offer a variety of technical services, including nanocarrier-mediated RNAi technology, which provides enhanced protection for double-stranded RNAs (dsRNAs), ensures that they remain intact as they enter the target cell, and ultimately improves RNAi efficiency.

Vector-mediated RNAi provides a reliable platform for sustained gene silencing and offers a stable and effective solution for long-term therapeutic programs.

Lentiviral-mediated RNAi service

The use of lentiviral vectors to deliver small RNA molecules directly into host cells ensures long-lasting, stable gene suppression, making it an indispensable part of gene therapy, especially when long-term silencing is required to achieve a therapeutic effect. Lentivirus-mediated RNAi provides a powerful tool for complex diseases that require precise and sustained gene silencing.

Our lentiviral-mediated RNAi service provides a reliable mechanism for achieving durable gene silencing by delivering siRNA directly to the relevant cell type.

Our Workflow of RNA Interference Technology

• Target gene selection. Select appropriate target genes by analyzing the genes related to the disease. And understand the function of target genes and their role in pathology.
• siRNA design and synthesis. This process includes siRNA sequence design. We can help customers design siRNA sequences specific to target genes and obtain siRNA by chemical synthesis or in vitro transcription.
• In vitro experiments. This process includes cell line selection, cell transfection experiments, and gene expression assays.
• Animal model experiment. This process we established animal models to administer siRNAs to animals through appropriate pathways and evaluate the therapeutic effects of siRNAs on the disease.
• Safety assessment. Evaluate the toxicity of siRNA or its vector through toxicity testing to ensure the safety of the host. And use immunogenicity test to detect whether siRNA triggers an immune response.

Fig.2 Our process of RNA interference. (CD Formulation)

Our Platforms for RNA Interference Technology

Highlights of Our RNA Interference Technology

• Our advanced technology platform allows us to maximize our ability to meet our clients' diverse project needs.
• Innovative R&D concepts ensure that we are always at the forefront of gene therapy formulation development, and that our clients can be confident in working with us.
• A strict quality control system ensures that we provide reliable technical support services to our customers.
• Our experienced team of experts allows us to support our clients in all aspects of their project development.

Explore Our RNA Interference Technology Related Services

Published Data

With an advanced technology platform and an experienced research team, CD Formulation aims to provide comprehensive technical support and reliable solutions for gene therapy formulation development. If you are interested in us, please feel free to contact us.